利妥昔单抗治疗丙型肝炎病毒相关冷球蛋白血症性膜增生性肾小球肾炎
Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis.
作者信息
Koratala Abhilash, Zeng Xu
机构信息
Division of Nephrology, Hypertension and Renal Transplantation University of Florida Gainesville Florida.
Division of Pathology, Immunology and Laboratory Medicine University of Florida Gainesville Florida.
出版信息
Clin Case Rep. 2018 Jan 4;6(2):442-443. doi: 10.1002/ccr3.1371. eCollection 2018 Feb.
Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.
与混合性冷球蛋白血症相关的膜增生性肾小球肾炎是丙型肝炎病毒（HCV）感染相关肾病中最常见的形式。利妥昔单抗是一种抗CD20单克隆抗体，是治疗严重和/或难治性HCV相关血管炎的有效药物，像我们的患者那样，使用该药可能无需进行透析。
Zotero 插件